BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 at HC Wainwright

BioXcel Therapeutics (NASDAQ:BTAI) had its price objective decreased by HC Wainwright from $7.00 to $5.00 in a report released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.54) EPS.

Several other brokerages also recently commented on BTAI. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research report on Friday, August 30th. UBS Group dropped their price target on BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th.

BioXcel Therapeutics Stock Performance

Shares of BTAI stock opened at $0.60 on Monday. The stock’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $1.30. BioXcel Therapeutics has a twelve month low of $0.51 and a twelve month high of $5.62. The company has a market capitalization of $22.52 million, a price-to-earnings ratio of -0.12 and a beta of 0.28.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.55. The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the previous year, the business posted ($1.83) earnings per share. On average, analysts forecast that BioXcel Therapeutics will post -1.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BTAI. Point72 Asia Singapore Pte. Ltd. bought a new position in BioXcel Therapeutics in the 2nd quarter worth approximately $39,000. Rosalind Advisors Inc. acquired a new stake in shares of BioXcel Therapeutics during the 2nd quarter worth approximately $51,000. XTX Topco Ltd grew its holdings in shares of BioXcel Therapeutics by 49.0% during the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after purchasing an additional 15,291 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of BioXcel Therapeutics during the 4th quarter worth approximately $176,000. Finally, Vanguard Group Inc. grew its holdings in shares of BioXcel Therapeutics by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock worth $3,100,000 after purchasing an additional 9,912 shares in the last quarter. 30.68% of the stock is owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.